SK Life Science Publishes Updated Real-World Experience on Cenobamate in Epilepsia Based on Recent 100,000 Patient Exposure Milestone

PARAMUS, N.J., March 13, 2024 /PRNewswire/ — SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd., a global biotech focused on developing treatments for central nervous system (CNS) disorders and oncology, today announced an update on the use of cenobamate, an…